140 related articles for article (PubMed ID: 29553932)
1. Nuclear Imaging Enters a New Era: Combining Diagnosis and Therapy, Nuclear Medicine Has the Potential to Advance Cancer Treatment and Care.
Mertz L
IEEE Pulse; 2018; 9(2):4-8. PubMed ID: 29553932
[TBL] [Abstract][Full Text] [Related]
2. An introduction to the clinical practice of theranostics in oncology.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
[TBL] [Abstract][Full Text] [Related]
3. Nuclear Medicine in Cancer Theranostics: Beyond the Target.
Taïeb D; Hicks RJ; Pacak K
J Nucl Med; 2016 Nov; 57(11):1659-1660. PubMed ID: 27445288
[No Abstract] [Full Text] [Related]
4. Nuclear medicine and oncology.
Lind P; Gallowitsch HJ
Wien Med Wochenschr; 2012 Oct; 162(19-20):405-6. PubMed ID: 23099624
[No Abstract] [Full Text] [Related]
5. Theranostic and nanotheranostic probes in nuclear medicine.
Drude N; Tienken L; Mottaghy FM
Methods; 2017 Nov; 130():14-22. PubMed ID: 28698069
[TBL] [Abstract][Full Text] [Related]
6. Nuclear oncology in Cancer Imaging 2011.
Miles K
Cancer Imaging; 2012 May; 12(1):185-6. PubMed ID: 22750163
[No Abstract] [Full Text] [Related]
7. Biocompatible PEGylated bismuth nanocrystals: "All-in-one" theranostic agent with triple-modal imaging and efficient in vivo photothermal ablation of tumors.
Li Z; Liu J; Hu Y; Li Z; Fan X; Sun Y; Besenbacher F; Chen C; Yu M
Biomaterials; 2017 Oct; 141():284-295. PubMed ID: 28709019
[TBL] [Abstract][Full Text] [Related]
8. [PET/CT: Molecular Imaging and Theranostics for Radionuclide Therapy].
Derlin T; Bengel FM
Pneumologie; 2017 Jan; 71(1):48-62. PubMed ID: 28114710
[No Abstract] [Full Text] [Related]
9. Liquid metal based theranostic nanoplatforms: Application in cancer therapy, imaging and biosensing.
Kulkarni S; Pandey A; Mutalik S
Nanomedicine; 2020 Jun; 26():102175. PubMed ID: 32151749
[TBL] [Abstract][Full Text] [Related]
10. Construction of iron oxide nanoparticle-based hybrid platforms for tumor imaging and therapy.
Hu Y; Mignani S; Majoral JP; Shen M; Shi X
Chem Soc Rev; 2018 Mar; 47(5):1874-1900. PubMed ID: 29376542
[TBL] [Abstract][Full Text] [Related]
11. [Targeted Radioisotope Therapy-Current Status and Future Perspectives].
Higashi T
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1391-1395. PubMed ID: 30382030
[TBL] [Abstract][Full Text] [Related]
12. The potential application of PET/MRI to clinical Nuclear Medicine.
Freeman L; Blaufox MD
Semin Nucl Med; 2015 Jul; 45(4):267. PubMed ID: 26050654
[No Abstract] [Full Text] [Related]
13. [New challenges and perspectives in nuclear medicine imaging].
Borbély K
Magy Onkol; 2014 Dec; 58(4):232-8. PubMed ID: 25517440
[TBL] [Abstract][Full Text] [Related]
14. Cancer-Targeted Nanotheranostics: Recent Advances and Perspectives.
Ma Y; Huang J; Song S; Chen H; Zhang Z
Small; 2016 Sep; 12(36):4936-4954. PubMed ID: 27150247
[TBL] [Abstract][Full Text] [Related]
15. Imaging in prostate cancer with multiparametric magnetic resonance imaging and gallium positron emission tomography-computed tomography: 'the real deal'?
Lawrentschuk N
BJU Int; 2015 Apr; 115 Suppl 5():1-2. PubMed ID: 25828170
[No Abstract] [Full Text] [Related]
16. Antibody-targeted nanoparticles for cancer treatment.
Carter T; Mulholland P; Chester K
Immunotherapy; 2016 Jul; 8(8):941-58. PubMed ID: 27381686
[TBL] [Abstract][Full Text] [Related]
17. [The 42nd Scientific Meeting: Perspectives of Internal Medicine; Considerations to treatment and care of cancer by internists in the era of increasing cancer mortality; 3. Current Status of Diagnosis and Treatment of Cancer; 1) Recent diagnostic imaging for cancer].
Sakai S
Nihon Naika Gakkai Zasshi; 2015 Mar; 104(3):436-42. PubMed ID: 26571722
[No Abstract] [Full Text] [Related]
18. Nuclear medicine theranostics comes of age.
Herrmann K; Kraus BJ; Hadaschik B; Kunikowska J; van Poppel H; N'Dow J; Sartor O; Oyen WJG
Lancet Oncol; 2021 Nov; 22(11):1497-1498. PubMed ID: 34735807
[No Abstract] [Full Text] [Related]
19. [Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology].
Schaefer N; Prior J
Ther Umsch; 2019 Sep; 76(4):167-172. PubMed ID: 31498036
[TBL] [Abstract][Full Text] [Related]
20. pH-Responsive, Self-Sacrificial Nanotheranostic Agent for Potential In Vivo and In Vitro Dual Modal MRI/CT Imaging, Real-Time, and In Situ Monitoring of Cancer Therapy.
Yue L; Wang J; Dai Z; Hu Z; Chen X; Qi Y; Zheng X; Yu D
Bioconjug Chem; 2017 Feb; 28(2):400-409. PubMed ID: 28042941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
